The sector that'll grow 480% this year, expert says

Can you smell that? That's the fragrance of a booming industry, which is still in a startup phase in Australia.

| More on:
cannabis leaves on a rising line graph representing growth of ASX cannabis share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There is a sector in Australia that's about to grow its revenue by 478% in the current financial year, according to one analyst.

Consumer research firm IBISWorld revealed Tuesday that the medical cannabis manufacturing industry is currently experiencing a boom despite the still-remaining legal hurdles.

"The strict regulatory framework regarding the manufacture of medical cannabis products has limited the sector's growth over the past five years," said IBISWorld senior industry analyst Will Chapman.

"However, the recent determination by the Therapeutic Goods Administration to allow over-the-counter [cannabidiol] products to be sold without a prescription is expected to drive significant revenue growth in the years ahead."

The industry produces medicines and consumables based on one of two ingredients extracted from the cannabis plant: cannabidiol (CBD) and tetrahydrocannabinol (THC).

CBD is a non-psychoactive ingredient used as a pain killer and an anti-convulsant. THC is the stuff that gives you "a high" but can be used to treat pain and nausea, low appetite and insomnia.

Recreational use for cannabis has been legalised in Canada and some US states. There is no sign of such a development yet in Australia, but IBISWorld reckons this won't stop local cannabis businesses from growth.

"It will take time for new medical cannabis products to be approved, but medicines derived from cannabis will eventually appear on pharmacy shelves," said Chapman.

Banks are offering massive finance to cannabis companies

The sector in Australia is still very much in the startup phase – so it's coming off a low base. 

Nevertheless, after seeing total revenue of just $5.4 million in the 2020 financial year, IBISWorld has forecast the current year will end with $31.2 million.

But there's still plenty of growth to come, it reported.

"Overall, medical cannabis manufacturing revenue is projected to rise at an annualised 79.1% over the five years through 2025-26, to $575.2 million," said Chapman.

"IBISWorld anticipates employment in this industry to reach 1,500 by 2025-26."

There are a few cannabis businesses listed on the ASX.

The Motley Fool reported last month Zelira Therapeutics Ltd (ASX: ZLD) had a stunning 2020, with the share price spiking up 67%. Althea Group Holdings Ltd (ASX: AGH) returned a nice 14% to its investors over the calendar year.

IBISWorld singled out Cann Group Ltd (ASX: CAN) as a "major player" in the Australian industry, with a 24% market share in the 2020 financial year.

Privately owned Little Green Pharma was also named by the analysis firm as a player to watch.

Banks have already recognised the huge potential, according to Chapman, lending out large sums to cannabis startups.

"The growth opportunities in the budding cannabis industry have not gone unnoticed by Australian financiers. In March 2020, start-up CannaPacific secured a $3.5 million debt facility from Westpac Banking Corp (ASX: WBC). Cann Group secured a $50 million credit facility from National Australia Bank Ltd (ASX: NAB) in November 2020," he said.

The ultimate milestone

Recreational legalisation may remain politically unpalatable in the near future in Australia. But the local industry's current focus is to get a cannabis-based medicine on the Australian register of Therapeutic Goods for domestic supply.

There is currently none on that hallowed list.

"For many start-up cannabis businesses, the ultimate goal is to have the medical benefits of cannabis recognised and their products accepted among medical professionals," Chapman said.

"Achieving the listing of cannabis products on the Pharmaceutical Benefits Scheme would be a major win for cannabis products."

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Magnifying glass on a rising interest rate graph.
Share Market News

Will the RBA finally cut interest rates next week?

Let's see what economists are saying about the central bank's meeting.

Read more »

A couple sits on a sofa, each clutching their heads in horror and disbelief, while looking at a laptop screen.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors endured a rough Friday to close the trading week today.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Broker Notes

7 ASX All Ords shares elevated to 'strong buy' status in October

The brokers turned bullish on these ASX companies last month.

Read more »

A businessman compares the growth trajectory of property versus shares.
Share Market News

How ASX shares vs. property performed in October

The national home value rose for the 21st consecutive month while the ASX 200 dipped.

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

The worst 3 ASX 200 stocks to buy and hold in October unmasked

You would have done well to avoid these three ASX 200 stocks in October.

Read more »

A female Woolworths customer leans on her shopping trolley as she rests her chin in her hand thinking about what to buy for dinner while also wondering why the Woolworths share price isn't doing as well as Coles recently
52-Week Lows

Why is the Woolworths share price at its lowest point since 2020?

We haven't seen Woolies shares this low since COVID.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why AFT, Amcor, Corporate Travel, and Macquarie shares are falling today

These shares are ending the week in the red. But why?

Read more »